{"entity":{"id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","aka":[],"tldr":"A phase 2 trial of adebrelimab in triple-negative breast cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","summary":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. is a phase 2, randomised interventional study registered as NCT06771609 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 150 participants, started 2024-09-10 and due to reach its primary completion in 2028-09-10. Interventions recorded: Adebrelimab + VEX metronomic chemotherapy + radiotherapy; Adebrelimab + VEX metronomic chemotherapy. Conditions listed: Advanced Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Subjects with metastatic triple-negative breast cancer, with clear clinical data records; specific reference to the \"American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06771609","url":"https://clinicaltrials.gov/study/NCT06771609"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06771609","phase":"2","setting":"Evaluate the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy With or Without Radiotherapy in Advanced Triple-negative Breast Cancer: a Prospective, Multicenter, Randomized Controlled Phase II Clinical Trial.","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06771609/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}